Difference between revisions of "Quisinostat (JNJ-26481585)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
m |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
===[[Cutaneous T-cell lymphoma]]=== | ===[[Cutaneous T-cell lymphoma]]=== | ||
| − | # Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. [https:// | + | # Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. [https://doi.org/10.1111/bjd.14427 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26836950/ PubMed] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' JNJ-26481585 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 11: | Line 14: | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
| − | [[Category:Cutaneous T-cell lymphoma medications]] | + | [[Category:Cutaneous T-cell lymphoma medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 12:18, 12 January 2024
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Quisinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis.
Preliminary data
Cutaneous T-cell lymphoma
- Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. link to original article PubMed
Also known as
- Code name: JNJ-26481585